Communiqués Precision BioSciences, Inc.

Actions

DTIL

US74019P2074

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 14/08/2026			Varia. 5j.	Varia. 1 janv.
7,430 ^USD	+1,78%		-0,80%	+78,61%

06/08	Precision BioSciences, Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI
27/07	Precision BioSciences, Inc. annonce des changements au sein de sa direction générale	CI

Communiqués

06/08	Precision BioSciences: Q2 Earnings Snapshot	AQ
06/08	Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update	BU
03/08	Precision BioSciences to Report Second Quarter 2026 Financial Results on August 6, 2026	AQ
31/07	Precision BioSciences to Report Second Quarter 2026 Financial Results on August 6, 2026	BU
27/07	Precision BioSciences Announces Changes to Senior Leadership Team to Support Advancement of Programs Through Next Set of Clinical Milestones	BU
10/07	Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)	BU
29/06	Precision BioSciences Announces Inclusion in the Russell 2000® Index Expanding Market Visibility with Institutional Investors	BU
27/05	Precision BioSciences Announces New and Late-Breaking PBGENE-HBV Clinical Data from the ELIMINATE-B Study at European Association for the Study of the Liver Congress 2026	BU
21/05	Precision BioSciences to Host Investor Webcast to Discuss Late-Breaking PBGENE-HBV Data from ELIMINATE-B Trial Presented at European Association for the Study of the Liver Congress 2026	BU
14/05	Precision BioSciences Presents New Preclinical Data Supporting the Advancement of PBGENE-DMD into Clinic at the American Society of Gene & Cell Therapy 2026 Annual Meeting	BU
05/05	Precision BioSciences: Q1 Earnings Snapshot	AQ
05/05	Precision BioSciences Reports First Quarter 2026 Financial Results and Provides Business Update	BU
30/04	Precision BioSciences to Report First Quarter 2026 Financial Results on May 5, 2026	BU
29/04	Precision BioSciences Activates First Clinical Trial Site and Begins Patient Enrollment in Phase 1/2 FUNCTION-DMD Study	BU
28/04	Precision BioSciences Announces Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 2026 Annual Meeting	BU
27/04	Precision BioSciences Announces Grant of Inducement Awards under Nasdaq Listing Rule 5635(4)	AQ
24/04	Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)	BU
22/04	Precision BioSciences Announces Late-Breaking Poster Presentation for PBGENE-HBV at European Association for the Study of the Liver Congress 2026	BU
15/04	Precision BioSciences Expands ELIMINATE-B Trial Following Clinical Trial Application Approval in Two European Countries	BU
08/04	Precision BioSciences to Participate in the 25th Annual Needham Virtual Healthcare Conference	BU
12/03	Precision BioSciences: Q4 Earnings Snapshot	AQ
12/03	Precision BioSciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Update	BU
11/03	Precision BioSciences Receives U.S. Patent Allowances Covering the PBGENE-HBV Program	BU
10/03	Precision BioSciences Presents Preclinical PBGENE-DMD Data Highlighting Durable Dystrophin Expression and Functional Benefit at the Muscular Dystrophy Association Clinical & Scientific Conference 2026	BU
09/03	Precision BioSciences to Report Fourth Quarter and Fiscal Year 2025 Results on March 12, 2026	BU